drug · small molecule
pelabresib
Phase 3updated 6mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 9 investigational indications.
targets
Bromodomain and extra-terminal motif (BET)
all catalysts(0)
nothing on the calendar yet
Trials studying pelabresib
- phase3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- phase1A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy Participants
- phase1Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
- phase1Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
- phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- phase3Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
- phase2A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
- phase1Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
News(3)
- Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bidGeron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…fiercebiotech · 19d ago
- Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran failNovartis CEO Vas Narasimhan has insisted that the phase 3 fail for del-desiran is just a “bump” in the Swiss pharma’s wider plans for the drug, despite costing the company an estimated $1.9 billion.fiercebiotech · 21d ago
- Novartis shareholder calls for board overhaul following costly deal setbacks: ReutersNovartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board’s oversight of dealmaking.fiercebiotech · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that